Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | AGXT | P21549 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229812 | 0.86 | — | — | |
| SCHEMBL198803 | 0.86 | ERN1 (0.47) | ERN1PTGS2IDO1AGXTMAOB | |
| SCHEMBL11313016 | 0.79 | ERN1 (0.51) | ERN1PTGS2IDO1AGXTMAOB | |
| SCHEMBL5800316 | 0.79 | ACACB (0.41) | MAOBHRH3 | |
| SCHEMBL7265564 | 0.79 | ERN1 (0.49) | ERN1AGXTNAAAL3MBTL1 | |
| SCHEMBL134443 | 0.78 | IDO1 (0.46) | ERN1PTGS2IDO1AGXTMAOB | |
| SCHEMBL12648082 | 0.77 | AGXT (0.54) | ERN1PTGS2IDO1AGXTMAOB | |
| SCHEMBL13497923 | 0.77 | ERN1 (0.42) | ERN1PTGS2IDO1AGXTTDP1 | |
| SCHEMBL3146138 | 0.77 | IDO1 (0.61) | ERN1IDO1AGXTNAAA | |
| SCHEMBL12736280 | 0.77 | AGXT (0.54) | ERN1PTGS2IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | ERN1 1291/4885PTGS2 294/4885IDO1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.